e-learning
resources
ERJ
2002
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene
Libura J., Bettens F., Radkowski A., Tiercy J.M., Piguet P.F.
Source:
Eur Respir J 2002; 19: 912-918
Journal Issue:
May
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Libura J., Bettens F., Radkowski A., Tiercy J.M., Piguet P.F.. Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene. Eur Respir J 2002; 19: 912-918
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
Lung function assessment in octogenarians with lung cancer diagnosis
An atypical presentation of granulomatosis with polyangiitis (GPA) with pituitary involvement
Related content which might interest you:
Tumour necrosis factor-α and lymphotoxin-α gene polymorphisms in cystic fibrosis lung disease
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
Clinical course of cystic fibrosis lung disease and tumour necrosis factor-β gene polymorphism
Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health
Year: 2008
Tumor necrosis factor-α gene polymorphism and inflammatory process in cystic fibrosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 403s
Year: 2005
Tumor necrosis factor-alpha and CD4/CD8 ratio in patients with hypersensitivity pneumonitis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis
Source: Eur Respir J 2003; 21: 421-428
Year: 2003
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy
Source: Eur Respir J 2001; 18: Suppl. 33, 233s
Year: 2001
Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients
Source: Eur Respir J 2006; 28: Suppl. 50, 522s
Year: 2006
Tumor necrosis factor α in chronic pulmonary diseases of children
Source: Eur Respir J 2002; 20: Suppl. 38, 193s
Year: 2002
Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis
Year: 2013
Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy.
Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases
Year: 2017
The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis
Source: Eur Respir J 2006; 28: Suppl. 50, 542s
Year: 2006
Correlation of IL-1 alpha and IL-4 promotor region gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis
Source: Annual Congress 2006 - Systemic diseases, environmental and genetic factors in interstitial lung disease
Year: 2006
Resistance of BAL immune cells to apoptosis in interstitial lung diseases (ILD) with high local tumor necrosis factor-α (TNFα) levels as a possible consequence of common TNF receptor type 2 expression
Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease
Year: 2008
Role of tumour necrosis factor-α receptor p75 in cigarette smoke-induced pulmonary inflammation and emphysema
Source: Eur Respir J 2006; 28: 102-112
Year: 2006
Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Circulating monocytes from interstitial lung disease patients show an activated phenotype
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014
Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up
Source: International Congress 2016 – Mixed-up imaging of various chest diseases
Year: 2016
Analysis of tumor necrosis factor receptor 1 (TNFR1) polymorphisms in patients with cryptogenic fibrosing alveolitis
Source: Eur Respir J 2001; 18: Suppl. 33, 411s
Year: 2001
B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept